BAAM
CUE icon

Baker Avenue Asset Management’s Cue Biopharma CUE Stock Holding History

Baker Avenue Asset Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,111
Closed -$116K – 429
2024
Q2 		$116K Buy
3,111
+2,032
+188% +$100K ﹤0.01% 363
2024
Q1 		$61.2K Hold
1,079
– – ﹤0.01% 356
2023
Q4 		$85.5K Hold
1,079
– – ﹤0.01% 349
2023
Q3 		$74.5K Hold
1,079
– – ﹤0.01% 465
2023
Q2 		$118K Buy
1,079
+1,021
+1,760% +$120K 0.01% 406
2023
Q1 		$6.25K Hold
58
– – ﹤0.01% 840
2022
Q4 		$4.99K Buy
+58
New +$5.3K ﹤0.01% 821

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Baker Avenue Asset Management's CUE Position: Q3 2024 in Review

Baker Avenue Asset Management sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 3,111 shares — an estimated $116K sold.

Baker Avenue Asset Management first reported a position in CUE in Q4 2022 and held it in 7 quarters. The position peaked at $118K in Q2 2023. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

  • Baker Avenue Asset Management reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
  • Baker Avenue Asset Management sold 3,111 Cue Biopharma shares in Q3 2024, an estimated $116K.
  • Baker Avenue Asset Management first reported a position in Cue Biopharma in Q4 2022 and held it in 7 quarters.
  • Baker Avenue Asset Management's Cue Biopharma position peaked at $118K in Q2 2023.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on Baker Avenue Asset Management's 13F filing for Q3 2024, filed 4 Nov 2024.